Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.
Gandhi MM, Ricciuti B, Harada G, Repetto M, Gildenberg MS, Singh A, Li YY, Gagné A, Wang X, Aizer A, Fitzgerald K, Nishino M, Alessi J, Pecci F, Di Federico A, Fisch A, Drilon A, Nardi V, Sholl L, Awad MM, Rotow J. Gandhi MM, et al. Among authors: drilon a. JCO Precis Oncol. 2023 Sep;7:e2300295. doi: 10.1200/PO.23.00295. JCO Precis Oncol. 2023. PMID: 37972337 Free PMC article.
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Gautschi O, et al. Among authors: drilon a. J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13. J Clin Oncol. 2017. PMID: 28447912 Free PMC article.
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O. Drilon A, et al. J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11. J Thorac Oncol. 2018. PMID: 30017832 Free PMC article.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. Sabari JK, et al. Among authors: drilon a. Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334. Ann Oncol. 2018. PMID: 30165371 Free PMC article.
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.
Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Farago AF, et al. Among authors: drilon a. JCO Precis Oncol. 2018;2018:PO.18.00037. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23. JCO Precis Oncol. 2018. PMID: 30215037 Free PMC article.
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.
Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA. Offin M, et al. Among authors: drilon a. JCO Precis Oncol. 2018;2:PO.18.00126. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. JCO Precis Oncol. 2018. PMID: 30957057 Free PMC article. No abstract available.
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A. Offin M, et al. Among authors: drilon a. JCO Precis Oncol. 2019;3:PO.18.00386. doi: 10.1200/PO.18.00386. Epub 2019 May 16. JCO Precis Oncol. 2019. PMID: 31192313 Free PMC article. No abstract available.
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Awad MM, et al. Among authors: drilon a. Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11. Lung Cancer. 2019. PMID: 31200835 Free PMC article.
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. Guo R, et al. Among authors: drilon a. J Thorac Oncol. 2019 Sep;14(9):1666-1671. doi: 10.1016/j.jtho.2019.06.009. Epub 2019 Jun 20. J Thorac Oncol. 2019. PMID: 31228623 Free PMC article.
257 results